PDF, Patent Landscape Report on Atazanavir - WIPO

More documents

Recommendations

Info

SECTION 7: SPECIFIC ELEMENTS OF DEVELOPMENTFOUNDER COMPOSITIONSThe founder composition for Atazanavir, invented at Novartis (then Ciba-Geigy) waspresented earlier as a citation map (Figure 10), but the map is repeated here showing bothforward and backward citations (Figure 29). The backward references represent earlier artreferenced by Novartis, and because the patent was issued, it implies that the compositionthat was later named Atazanavir was new compared to earlier art. The earlier art includeswork by Novartis, Abbott, Merck and Roche (Figure 30). The Roche document isparticularly interesting. The map in Figure 31 is a forward citation map from the highlightedRoche patent, and it is extraordinarily highly cited, as well as being the founder case for aRoche protease inhibitor drug. As can be seen from the 3-generation citation map in Figure31, the Roche patent is far more highly cited than the Atazanavir document, and contains3950 citing documents published between 1990 and 2011. This high rate of citation isprobably because it was the ground-breaker for this class of drugs, showing in 1989 thatthe HIV-aspartyl protease target was amenable to inhibition that resulted in diseasemodulation. Looking for very highly and persistently cited documents such as the Rochepatent, and then analyzing their downstream references can allow insight into how the mostfoundational work in a field was followed up.Figure 29. Citation map of the founder composition patent for AtazanavirGame-ChangerProteaseInhibitor <strong>Patent</strong>Hoffmann La RocheFounderATZ<strong>Patent</strong>BackwardForward34
Figure 30. References made by the Founder <strong>Patent</strong>35
Page 4 and 5: ContentsSECTION 1: THE TWO OBJECTIV
Page 7 and 8: collection for nuggets of intellige
Page 9 and 10: CHEMICAL NAMINGChemical naming conv
Page 11 and 12: Figure 2: Legal Status for Novartis
Page 13 and 14: name, but after the patent protecti
Page 15 and 16: STAGE TWO CLINICAL SEARCHTo be more
Page 17 and 18: CLINICAL COLLECTIONThis is an examp
Page 19 and 20: THE FOUNDER PATENT AND ITS DOWNSTRE
Page 21 and 22: CHEMICAL COLLECTIONThis is an examp
Page 23 and 24: SECTION 5: GENERAL OVERVIEW OF THE
Page 25 and 26: FAMILY MEMBER COUNTRIESLooking at p
Page 27 and 28: The crossover between categories is
Page 29 and 30: THE DEVELOPER’S OWN TIMELINEThe A
Page 31 and 32: Several of the representative paten
Page 33 and 34: Figure 25. Emphasis Matrix for Sele
Page 35: PATENT QUALITY INDICATORS FOR SELEC
Page 39 and 40: FORMULATIONSEven before a drug is a
Page 41 and 42: Figure 34. References to Bristol My
Page 43 and 44: PROPRIETARY DRUGS AND LITIGATIONThe
Page 45 and 46: TWO DRUGS DIRECTED AT THE SAME TARG
Page 47 and 48: Citations to this document mainly c
Page 49 and 50: USING OVERLAP TO FIND COMBINATIONS
Page 51 and 52: INTERNATIONAL PATENT CLASSIFICATION
Page 53 and 54: ased on the IPC, but with sometimes
Page 55 and 56: DERWENT MANUAL CODESDWPI Manual Cod
Page 58: For more information contact WIPO a

PDF, Patent Landscape Report on Atazanavir - WIPO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?